Enliven Therapeutics, Inc. (ELVN) is a biotechnology company that is deeply rooted in scientific research and innovation. The company is committed to discovering and developing novel therapies for patients suffering from rare and serious diseases, focussing primarily on oncology, immunology, and neurology.
Although ELVN is still relatively young in the industry, its strides towards developing new methods for treating complex diseases are significant and groundbreaking. This vision is driven by a team of highly skilled scientists and medical professionals who leverage years of experience in drug discovery, clinical development, and regulatory affairs. Their focus spans from decoding the mysteries of disease pathogenesis to identifying novel targets and developing precision therapies.
ELVN's broad therapeutic focus areas are represented by a robust pipeline of projects in various stages of research and clinical development. The company's commitment to advancing science and helping patients is evident in its fast-paced drug development and research initiatives. Each project is seen as an opportunity to bring new hope to patients living with complex and challenging diseases around the world.
Part of ELVN's strength lies in its collaborative approach. The company cultivates strategic partnerships with leading academic institutions, hospitals, and other biotech companies to accelerate research efforts and expand its capabilities. These collaborations play a crucial role in ELVN's success and underscore the importance of cooperation in addressing the world's pressing healthcare challenges.
Enliven Therapeutics operates on the core principle of transforming the lives of patients through innovative science. It strives for intellectual curiosity, scientific rigor, and the pursuit of excellence in all its endeavors. This relentless pursuit of innovations places ELVN at the forefront of biotechnology companies trying to break new grounds in medicine.
ELVN is also committed to maintaining the highest ethical standards in its operations. The company respects the contributions of everyone involved in the process of drug development and research, giving thanks to its diligent employees, committed partners, and especially the brave patients who participate in its clinical trials.
Interestingly, ELVN recognizes the need for constant learning and improvement. Besides pushing the boundaries of science, it also believes in learning from patients and their experiences. After all, these insights are invaluable in shaping research directions and therapeutic strategies.
In short, Enliven Therapeutics, Inc. is more than just a biotech company. It's a mission-driven organization that places patients at the center of everything they do. With a rich pipeline of innovative projects, strategic collaborations, and an unwavering commitment to excellence, ELVN is indeed on a promising path to transform medical science and patient care.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
An insider at Enliven Therapeutics (ELVN) recently sold shares valued at $251,754, as disclosed in a recent SEC filing. The article, published on MarketScreener, highlights this transaction and provides additional context on the company's recent activities, including conference presentations and analyst ratings. Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for conditions like chronic myeloid leukemia and HER2-positive cancers.
Benjamin Hohl, the Chief Financial Officer of Enliven Therapeutics, Inc. (NASDAQ:ELVN), recently exercised stock options for 3,982 shares at $14.85 per share and subsequently sold 6,018 shares in three separate transactions on September 17, 2026. These transactions, executed under a Rule 10b5-1 trading plan adopted in March 2026, resulted in weighted average sales prices ranging from $50.0286 to $51.4929. Following these activities, Hohl directly holds 38,000 shares and retains options for 181,018 shares.
Enliven Therapeutics, Inc. (ELVN) is a clinical-stage biopharmaceutical company focused on developing small molecule inhibitors for cancer, with two programs in Phase 1 trials targeting chronic myeloid leukemia and non-small cell lung cancer. Despite lacking current revenue, the company holds a market cap of $3.68 billion and is seen as a significant growth opportunity by analysts, who project an average 47.09% upside potential. Investors are advised to monitor clinical trial progress and regulatory milestones for future stock performance.
This article provides an AI-generated analysis of Enliven Therapeutics Inc. (NASDAQ: ELVN), indicating a neutral near and mid-term outlook with a potentially positive long-term bias. It outlines various institutional trading strategies, including long, breakout, and short positions, based on different risk profiles and time horizons. The analysis also highlights specific support and resistance levels, emphasizing risk-reward ratios for potential trades.
Enliven Therapeutics will present data from its ENABLE Phase 1 clinical trial for ELVN-001 at the SOHO Annual Meeting from September 9-12, 2026. The trial focuses on evaluating the safety and efficacy of ELVN-001, a highly selective small molecule kinase inhibitor, in chronic myeloid leukemia patients, particularly those with T315I mutations. This presentation aims to provide critical insights for future treatments and strengthen Enliven's position in precision medicine.
Handelsbanken Fonder AB acquired 17,300 shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) valued at approximately $878,000 during the second quarter. Institutional investors and hedge funds now collectively own 95.08% of the company's stock, while insider transactions show sales totaling $11.3 million over the past 90 days. Despite a recent earnings miss, analysts maintain a "Moderate Buy" rating with an average price target of $75.00 for ELVN.
William Blair initiated coverage on Enliven Therapeutics (NASDAQ: ELVN) with an Outperform rating, highlighting the potential of its lead drug candidate, ELVN-001, to transform chronic myeloid leukemia (CML) treatment. ELVN-001 has shown positive Phase 1 data, demonstrating significant major molecular response rates, and the company has a cash runway into 2030. Analysts believe ELVN-001 could disrupt the CML market due to its differentiated profile and effectiveness against resistance mutations to current market leaders.